SciRhom GmbH is an innovative biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. The company was founded in 2016 and is based in the Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near Munich.
SciRhom's approach is based on the targeted inhibition of iRhom2, a key regulator of the enzyme TACE (Tumor Necrosis Factor-alpha Converting Enzyme). TACE controls several important signaling pathways that play a role in inflammatory processes, including TNF-alpha, IL-6 and EGFR. However, direct inhibition of TACE has historically led to serious side effects. SciRhom bypasses this problem by targeting iRhom2, which selectively regulates the pro-inflammatory activities of TACE in immune cells without affecting its protective functions in other tissues.
The company is developing first-in-class antibodies against iRhom2, which have shown promising results in preclinical studies. These antibodies simultaneously block several important pro-inflammatory signaling pathways and may also restore protective signaling pathways. SciRhom is currently focused on developing therapies for rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and Lupus nephritis. The most advanced program, SR-878, is already in clinical development.
SciRhom's goal is to fundamentally improve the treatment of autoimmune diseases and improve the quality of life for millions of patients. The company is led by an experienced management team and a top-class scientific advisory board. SciRhom works closely with renowned research institutions such as the Hospital for Special Surgery (HSS) in New York. The company is supported by an international consortium of life science investors.
